In a study published in The New England Journal of Medicine, researchers investigated the effectiveness of the drug pembrolizamab on increasing survival rates in patients with advanced melanoma (Eggermont et al. 2018). In this randomized double-blind study, 514 patients received the drug and 505 patients received a placebo. Recurrence-free survival rates for both groups were measured after 15 months. After 15 months, 388 patients in the drug group and 308 patients in the placebo group experienced recurrence-free survival.

a. Find and compare the percentages that experienced recurrence-free survival.

b. Test the hypothesis that a greater proportion of patients taking the drug experienced recurrence-free survival than those taking the placebo. Use a significance level of 0.05.

c. Based on this study, do you think the drug pembrolizamab may beeffective in treating patients with advanced melanoma? Explain.